China Pharma Holdings (CPHI) Revenue (2010 - 2026)

China Pharma Holdings has reported Revenue for 17 years, with the latest figure at $983536.0 in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 13.44% year-over-year to $983536.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 7.07% YoY), and the FY2025 full-year result was $4.1 million, down 8.49% from the prior year.
• Revenue for Q1 2026 stood at $983536.0, down from $1.2 million in the prior quarter.
• The five-year high for Revenue was $2.9 million in Q4 2022, with the low at $756217.0 in Q3 2025.
• Historically, Revenue has averaged $1.5 million across 5 years, with a median of $1.2 million in 2025.
• Annual changes were most pronounced in 2023 — Revenue climbed 22.21% — and 2024, when it sank 47.25%.
• China Pharma Holdings' Revenue stood at $2.9 million in 2022, then fell by 26.41% to $2.1 million in 2023, then tumbled by 47.25% to $1.1 million in 2024, then advanced by 8.11% to $1.2 million in 2025, then declined by 19.78% to $983536.0 in 2026.
• The last three Revenue figures came in at $983536.0 (Q1 2026), $1.2 million (Q4 2025), and $756217.0 (Q3 2025), per Business Quant data.